ARG1 and familial pancreatic carcinoma: Similarly, treatment with EGFR inhibitor targeted therapy suppresses MDSCs and Arg1 expression, resulting in heightened levels of Th1 cytokines such as IL-12 and tumor necrosis factor-alpha (TNF-α) and reduced pancreatic cancer [50].